{"id":742176,"date":"2012-10-17T06:30:00","date_gmt":"2012-10-17T06:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/"},"modified":"2023-03-22T00:04:21","modified_gmt":"2023-03-22T04:04:21","slug":"victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/","title":{"rendered":"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside of the United States and Canada,<br \/>\n      announced today that VICTRELIS<sup>\u00ae <\/sup>(boceprevir) 200 mg Capsules,<br \/>\n      the company\u2019s oral treatment for chronic hepatitis C genotype 1<br \/>\n      infection, in combination with peginterferon alfa and ribavirin has<br \/>\n      received the Prix Galien USA Award for Best Pharmaceutical Agent.\n    <\/p>\n<p>\n      The Prix Galien USA Award recognizes the technical, scientific and<br \/>\n      clinical research skills and achievements necessary to develop<br \/>\n      innovative medicines and devices. It is considered the biomedical<br \/>\n      industry\u2019s highest accolade.\n    <\/p>\n<p>\n      &#8220;Merck is honored to have been chosen as a recipient of this prestigious<br \/>\n      award,&#8221; said Peter S. Kim, president of Merck Research Laboratories.<br \/>\n      &#8220;This achievement is a testament to the remarkable contributions of<br \/>\n      everyone at Merck who played a role in helping to bring VICTRELIS to<br \/>\n      market.\u201d\n    <\/p>\n<p>\n      The Prix Galien Award recognizes the pharmaceutical industry&#8217;s<br \/>\n      outstanding achievement in the development of new medicines. An<br \/>\n      internationally recognized award, the Prix Galien was founded in France<br \/>\n      in 1969 by French pharmacist, Roland Mehl and is considered the highest<br \/>\n      accolade for pharmaceutical research and development.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50443991&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=1&#038;md5=f66a4e66bb51ba34d38bbc81501b0782\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on Twitter, Facebook and YouTube.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that all of the expected synergies from the merger of Merck<br \/>\n      and Schering-Plough will not be realized, or will not be realized within<br \/>\n      the expected time period; the impact of pharmaceutical industry<br \/>\n      regulation and health care legislation in the United States and<br \/>\n      internationally; Merck\u2019s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck\u2019s patents and other<br \/>\n      protections for innovative products; and the exposure to litigation<br \/>\n      and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for VICTRELIS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&#038;esheet=50443991&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_pi.pdf&#038;index=2&#038;md5=30cbb0630f65beb9d20f63b519d5e15d\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf<\/b><\/a><b><br \/>\n      and Medication Guide for VICTRELIS at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_mg.pdf&#038;esheet=50443991&#038;lan=en-US&#038;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fv%2Fvictrelis%2Fvictrelis_mg.pdf&#038;index=3&#038;md5=5dfb9adecd7016c3ef23352fc58da66a\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20121017005506r1&#038;sid=sfsite1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media Contact: Caroline Lappetito, (267) 305-7639<br \/>Investor        Contact: Carol Ferguson, (908) 423-4465     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that VICTRELIS \u00ae (boceprevir) 200 mg Capsules, the company\u2019s oral treatment for chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin has received the Prix Galien USA Award for Best Pharmaceutical Agent. The Prix Galien USA Award recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices. It is considered the biomedical industry\u2019s highest accolade. &#8220;Merck is honored to have been chosen as a recipient of this prestigious award,&#8221; said Peter S. Kim, president of Merck Research Laboratories. &#8220;This achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring VICTRELIS to market.\u201d The Prix Galien Award recognizes the pharmaceutical industry&#8217;s outstanding achievement in the development of new medicines. An internationally<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742176","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that VICTRELIS \u00ae (boceprevir) 200 mg Capsules, the company\u2019s oral treatment for chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin has received the Prix Galien USA Award for Best Pharmaceutical Agent. The Prix Galien USA Award recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices. It is considered the biomedical industry\u2019s highest accolade. &quot;Merck is honored to have been chosen as a recipient of this prestigious award,&quot; said Peter S. Kim, president of Merck Research Laboratories. &quot;This achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring VICTRELIS to market.\u201d The Prix Galien Award recognizes the pharmaceutical industry&#039;s outstanding achievement in the development of new medicines. An internationally\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/\",\"name\":\"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx\",\"datePublished\":\"2012-10-17T06:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/","og_locale":"en_US","og_type":"article","og_title":"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that VICTRELIS \u00ae (boceprevir) 200 mg Capsules, the company\u2019s oral treatment for chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin has received the Prix Galien USA Award for Best Pharmaceutical Agent. The Prix Galien USA Award recognizes the technical, scientific and clinical research skills and achievements necessary to develop innovative medicines and devices. It is considered the biomedical industry\u2019s highest accolade. \"Merck is honored to have been chosen as a recipient of this prestigious award,\" said Peter S. Kim, president of Merck Research Laboratories. \"This achievement is a testament to the remarkable contributions of everyone at Merck who played a role in helping to bring VICTRELIS to market.\u201d The Prix Galien Award recognizes the pharmaceutical industry's outstanding achievement in the development of new medicines. An internationally","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:21+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/","name":"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx","datePublished":"2012-10-17T06:30:00+00:00","dateModified":"2023-03-22T04:04:21+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20121017005506r1&sid=sfsite1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/victrelis-boceprevir-awarded-2012-prix-galien-usa-best-pharmaceutical-agent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"VICTRELIS\u00ae (boceprevir) Awarded 2012 Prix Galien USA Best Pharmaceutical Agent"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"e6c47f6a-27b5-462c-a02d-b731b0584724","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742176\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742176"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}